

SYNTHESIS OF GEOMETRICAL ISOMERS  
OF 3-(3-ACETOXY AND  
3-CARBAMOYLOXY-1-PROPENYL)-  
CEPHALOSPORINS AND THEIR  
STRUCTURE-ACTIVITY  
RELATIONSHIPS

HAJIME KAMACHI, TAKAOKI OKITA,  
HIDEAKI HOSHI, SATSUKI OKUYAMA  
and TAKAYUKI NAITO†

Bristol-Myers Squibb Research Institute,  
2-9-3 Shimo-meguro, Meguro-ku, Tokyo 153, Japan

(Received for publication November 22, 1991)

In the course of our research program exploring new cephalosporins, we have found that 3-[(*Z*)-1-propenyl] derivatives, such as **BMY-28100** (cefprozil)<sup>1)</sup> and **BMY-28232**<sup>2)</sup>, showed Gram-negative activity superior to their corresponding 3-(*E*)-propenyl isomers, whereas 3-[(*E*)-3-quaternary-ammonio-1-propenyl]cephalosporins<sup>3)</sup> were more active than their corresponding *Z*-isomers against both Gram-positive and Gram-negative bacteria. **BEEBY** and **EDWARDS**<sup>4)</sup> reported the synthesis of *E*-isomer of 7-(2-thienylacetamido)-3-(3-acetoxy-1-propenyl)cephalosporin and its potent antibacterial activity, but did not describe on its *Z*-isomer. It is of interest to clarify the structure-activity relationships between the geometrical isomers of cephalosporins having a 3-acetoxy- or 3-carbamoyloxy-1-propenyl group at the C-3 position. Here we wish to report on the synthesis of three pairs of geometrical isomers of the above cephalosporins, **1**~**6** (Fig. 1), using the Wittig reaction for the introduction of the *Z*-propenyl groups and rearrangement of them to the *E*-propenyl groups. The structure-activity relationships between the geometrical isomers is described.

Synthesis of Cephalosporins **1** and **2** (Scheme 1)


3-[(*E*)-3-Carbamoyloxy-1-propenyl]cephalosporin (**1**) was synthesized from [(*Z*)-3-chloro-1-propenyl]cephem ester (**7**)<sup>3)</sup>. It was treated with  $\text{AgNO}_3$ <sup>5)</sup> in aqueous DMSO (4 hours at room temperature) to give **8** (65%;  $^1\text{H NMR}$  ( $\text{CDCl}_3$ )  $\delta$  6.93 (1H, d,  $J=16$  Hz, 3- $\text{CH}=\text{CH}$ )). Compound **8** was treated with trichloroacetylisocyanate<sup>6)</sup>, followed by successive treatment with TFA and 2N

$\text{Na}_2\text{CO}_3$ , to give **1** (13%;  $^1\text{H NMR}$  ( $\text{DMSO}-d_6$ )  $\delta$  6.96 (1H, d,  $J=16$  Hz, 3- $\text{CH}=\text{CH}$ )). 3-[(*Z*)-3-Carbamoyloxy-1-propenyl]cephalosporin (**2**) was synthesized by direct introduction of the (*Z*)-carbamoyloxypropenyl group to the C-3 side chain by the Wittig reaction. As 2-carbamoyloxyacetaldehyde was unstable<sup>7)</sup>, *N*-trityl-protected 2-carbamoyloxyacetaldehyde (**10**) was employed. Triethylamine was treated with allyl chloroformate in the presence of bis(trimethylsilyl)acetamide (2 equiv) in  $\text{CH}_2\text{Cl}_2$  (room temperature, overnight) to give allyl *N*-trityl carbamate (**9**) (91%; mp 97~98°C), which was subjected to ozonolysis in  $\text{CH}_2\text{Cl}_2$  at -78°C and subsequent treatment with dimethyl sulfide to give the aldehyde **10** (71%; mp 93~96°C). The ylide **11** was conventionally prepared<sup>1,2)</sup> by treatment of 7-*N*-Boc-3-chloromethylcephem ester with triphenylphosphine in  $\text{CH}_2\text{Cl}_2$  followed by treatment with 5N  $\text{Na}_2\text{CO}_3$ . The Wittig reaction of **11** and the aldehyde **10** in  $\text{CH}_2\text{Cl}_2$  (room temperature, 3 days), afforded 3-[(*Z*)-3-carbamoyloxy-1-propenyl]cephem **12** (42%;  $^1\text{H NMR}$  ( $\text{DMSO}-d_6$ )  $\delta$  6.23 (1H, d,  $J=12$  Hz, 3- $\text{CH}=\text{CH}$ )). Deblocking of **12** with  $\text{HCO}_2\text{H}-\text{HCl}$  (2:1, 1 hour, room temperature), gave **13** (66%;  $^1\text{H NMR}$  ( $\text{D}_2\text{O}+\text{NaHCO}_3$ )  $\delta$  6.22 (1H, d,  $J=12$  Hz, 3- $\text{CH}=\text{CH}$ )). Acylation of **13** with benzotriazol-1-yl (*Z*)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetate<sup>8)</sup> in DMF in the presence of  $\text{NaHCO}_3$  afforded **2** (34%;  $^1\text{H NMR}$  ( $\text{DMSO}-d_6$ )  $\delta$  6.36 (1H, d,  $J=12$  Hz, 3- $\text{CH}=\text{CH}$ )).

Synthesis of Cephalosporins **3**~**6** (Scheme 2)

Synthesis of 3-[(*Z*)-3-acetoxy-1-propenyl]cephalosporins (**4** and **6**) was by way of the 7-*N*-


Fig. 1. 3-[(*E*)- and (*Z*)-3-substituted-oxy-1-propenyl]cephalosporins.




Compound	R <sub>1</sub>	R <sub>2</sub>	*
<b>1</b>	CH <sub>3</sub>	OCONH <sub>2</sub>	<i>E</i>
<b>2</b>	CH <sub>3</sub>	OCONH <sub>2</sub>	<i>Z</i>
<b>3</b>	CH <sub>3</sub>	OCOCH <sub>3</sub>	<i>E</i>
<b>4</b>	CH <sub>3</sub>	OCOCH <sub>3</sub>	<i>Z</i>
<b>5</b>	H	OCOCH <sub>3</sub>	<i>E</i>
<b>6</b>	H	OCOCH <sub>3</sub>	<i>Z</i>

† Deceased.

Scheme 1. Synthesis of 3-carbamoyloxypropenylcephalosporins.



Scheme 2. Synthesis of 3-acetoxypropenylcephalosporins.




benzylidene-cephem-3-ylide **14**<sup>2)</sup>. The Wittig reaction of **14** with acetoxyacetaldehyde<sup>9)</sup> in the presence of excess LiBr (10 equiv) in DMF- $\text{CH}_2\text{Cl}_2$  (room temperature, overnight) gave the 3-(*Z*)-acetoxypropenyl-7-*N*-benzylidene-cephem (**15**). The benzylidene group of **15** was deblocked with the Girard T reagent to give the 7-aminocephem (**16**) (68% after crystallization from ether; mp 117~119°C;  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.25 (1H, d,  $J=12$  Hz, 3- $\text{CH}=\text{CH}$ )). Compound **16** was acylated with benzotriazol-1-yl (*Z*)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetate and (*Z*)-2-(2-tritylaminothiazol-4-yl)-2-trityloxyiminoacetate<sup>2)</sup> (THF, 18

hours, room temperature) and deblocked with  $\text{HCO}_2\text{H}-\text{HCl}$ <sup>2)</sup> to give **4** (37%;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  6.34 (1H, d,  $J=12$  Hz, 3- $\text{CH}=\text{CH}$ )) and **6** (36%;  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ )  $\delta$  6.35 (1H, d,  $J=12$  Hz, 3- $\text{CH}=\text{CH}$ )). In order to obtain the corresponding *E*-isomers, **3** and **5**, thermal isomerization of the propenyl group of **17** was attempted. The Wittig reaction of **11** with acetoxyacetaldehyde gave *Z*-(3-acetoxy-1-propenyl)cephem **17**, which was dissolved in toluene and heated under reflux for 2 days to afford *E*-(3-acetoxy-1-propenyl)cephem, **18** (51% after crystallization from ether; mp 161~163°C (dec);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.90 (1H, d,

Table 1. Test organisms.

Group	Organism	Number of strains
Gp-Ia	Penicillinase (Pen-ase)-negative <i>Staphylococcus aureus</i>	5
Gp-Ib	Pen-ase-positive <i>S. aureus</i>	5
Gn-Ia	Cephalothin(CET)-sensitive <i>Escherichia coli</i> (2 strains), <i>Klebsiella pneumoniae</i> (1) and <i>Proteus mirabilis</i> (2)	5
Gn-Ib	CET-resistant <i>E. coli</i> (3) and <i>K. pneumoniae</i>	5
Gn-II	<i>Morganella morganii</i> (1), <i>Enterobacter cloacae</i> (2) and <i>Serratia marcescens</i> (2)	5
Gn-III	<i>Pseudomonas aeruginosa</i>	7

Table 2. *In vitro* activity of the geometrical isomers of cephalosporins (Mueller-Hinton agar, 10<sup>6</sup> cfu/ml, 37°C, 18 hours).

Compound	R <sub>1</sub>	R <sub>2</sub>	*	Geometric mean of MIC (μg/ml)					
				Gp-Ia	Gp-Ib	Gn-Ia	Gn-Ib	Gn-II	Gn-III
1	CH <sub>3</sub>	OC(=O)NH <sub>2</sub>	<i>E</i>	1.1	1.8	0.044	0.17	0.91	> 50
2	CH <sub>3</sub>	OC(=O)NH <sub>2</sub>	<i>Z</i>	0.92	1.6	0.0082	0.087	0.79	28
3	CH <sub>3</sub>	OC(=O)CH <sub>3</sub>	<i>E</i>	0.53	0.80	0.019	0.087	0.53	> 50
4	CH <sub>3</sub>	OC(=O)CH <sub>3</sub>	<i>Z</i>	0.61	1.6	0.025	0.13	0.80	> 50
5	H	OC(=O)CH <sub>3</sub>	<i>E</i>	0.17	0.40	0.025	0.17	1.2	> 50
6	H	OC(=O)CH <sub>3</sub>	<i>Z</i>	0.30	0.40	0.029	0.11	0.91	> 50
20	H	H	<i>E</i>	0.23	0.61	0.46	2.1	33	> 50
21	H	H	<i>Z</i>	0.23	0.40	0.076	0.35	5.5	> 50
22	H	CH <sub>3</sub>	<i>E</i>	0.23	0.61	0.69	3.2	22	> 50
23	H	CH <sub>3</sub>	<i>Z</i>	0.26	0.40	0.20	0.79	7.3	> 50
24	CH <sub>3</sub>	N <sup>+</sup> (CH <sub>3</sub> ) <sub>3</sub>	<i>E</i>	0.23	0.80	0.011	0.076	0.087	2.4
25	CH <sub>3</sub>	N <sup>+</sup> (CH <sub>3</sub> ) <sub>3</sub>	<i>Z</i>	0.61	1.4	0.029	0.11	0.20	3.8
26	CH <sub>3</sub>		<i>E</i>	0.15	0.35	0.0094	0.038	0.057	1.7
27	CH <sub>3</sub>		<i>Z</i>	0.35	0.80	0.029	0.087	0.15	3.8
Cefotaxime				1.2	2.7	0.025	0.087	1.2	21

$J=16$  Hz, 3-CH=CH). Selective deblocking of **18** by treatment with *p*-toluenesulfonic acid (2 equiv) in acetonitrile (40°C, 40 minutes) gave 7-aminocephem **19** (84%; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.90 (1H, d,  $J=16$  Hz, 3-CH=CH)). *N*-Acylation of **19** with the active esters followed by deblocking gave the *E*-isomers **3** (46%; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 6.85 (1H, d,  $J=16$  Hz, 3-CH=CH)) and **5** (51%; <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>) δ 6.87 (1H, d,  $J=16$  Hz, 3-CH=CH)).

#### Structure-activity Relationships between The Geometrical Isomers

MICs of the cephalosporins **1** through **6**, together

with two pairs of the geometrical isomers of 7-[(*Z*)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-(1-alkenyl)cephalosporins<sup>2</sup>, **20** through **23**, and the two pairs of 7-[(*Z*)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-(3-quaternary ammonio-1-propenyl)cephalosporins<sup>3</sup>, **24** through **27**, were determined by two-fold serial agar dilution method in Mueller-Hinton agar. The test organisms consisted of six groups which are described in Table 1. The *in vitro* activity of the derivatives was assessed by the geometric means of MICs for each group of the test organisms and summarized in Table 2. As we already

reported<sup>2,3)</sup>, in the 3-(1-alkenyl)cephalosporins, which showed good Gp, rather weak Gn-Ib, weak Gn-II and very weak Gn-III activity, the *Z*-isomers, **21** and **23**, were as active as the corresponding *E*-isomers, **20** and **22**, against Gp-Ia and Gp-Ib, respectively, but they were much more active against Gn-Ia, Gn-Ib and Gn-II than the corresponding *E*-isomers. In contrast, in the cephalosporins having a quaternary ammonio group in 3-position of the propenyl group and showing high and broad anti-bacterial spectrum including good Gn-III activity, the *E*-isomers, **24** and **26** were more active than the corresponding *Z*-isomers, **25** and **27** against all groups of the strains. The cephalosporins synthesized in this study showed higher Gn-Ib and Gn-II activity than the 3-(1-alkenyl)cephalosporins with very weak Gn-III activity. Among them, the *Z*-isomer of 3-carbamoyloxypropenyl derivative, **2**, was much more active against Gn-Ia and slightly more active against the other groups of strains than the *E*-isomer **1**, while, in the 3-acetoxypentenyl derivatives, there were no significant differences between the activity of the *E*-isomers and their corresponding *Z*-isomers, although **3** (*E*-isomer) is slightly more active than **4** (*Z*-isomer) against all of the groups. In conclusion, the Gram-negative activity of 7-aminothiazol-oxyminoacetyl-cephalosporins having 3-(3-substituted-1-propenyl) group as well as the structure-activity relationships between their geometrical isomers depends on the substituent introduced into the 3-position of the propenyl group.

#### Acknowledgment

The authors express their appreciation to Dr. T. TSUNO and his associates of the Analytical Chemistry of this Institute for the spectral data, our associates of the Microbiology Laboratory for the microbiological data, Dr. H. KAWAGUCHI, the ex-president of this Institute and Dr. T. OKI, the director of this Institute for valuable discussion

and encouragement during this study.

#### References

- 1) NAITO, T.; H. HOSHI, S. ABURAKI, Y. ABE, J. OKUMURA, K. TOMATSU & H. KAWAGUCHI: Synthesis and structure-activity relationships of a new oral cephalosporin, BMY-28100 and related compounds. *J. Antibiotics* 40: 991~1005, 1987
- 2) KAMACHI, H.; Y. NARITA, T. OKITA, Y. ABE, S. IIMURA, K. TOMATSU, T. YAMASAKI, J. OKUMURA, T. NAITO, T. OKI & H. KAWAGUCHI: Synthesis and biological activity of a new cephalosporin, BMY-28232 and its prodrug-type esters for oral use. *J. Antibiotics* 41: 1602~1616, 1988
- 3) KAMACHI, H.; M. OKA, Y. NARITA, S. IIMURA, S. ABURAKI, H. YAMASHITA, K. TOMATSU, J. OKUMURA & T. NAITO: Synthesis of a new series of cephalosporins having 3-substituted-ammonio-1-propenyl group as the C-3 side chain. *J. Antibiotics* 43: 533~543, 1990
- 4) BEEBY, P. J. & J. A. EDWARDS: 3-(3-Substituted prop-1-enyl)cephalosporins. *J. Med. Chem.* 20: 1665~1668, 1977
- 5) GILMAN, H.; C. G. BRANNEN & R. K. INGHAM: Some tetraarylsilanes containing functional groups. *J. Am. Chem. Soc.* 78: 1689~1692, 1956
- 6) MURPHY, C. F.; R. E. KOEHLER & J. A. WEBBER: The conversion of deacetylcephalosporin C to a derivative of 7-(5-amino-5-carboxyvaleramido)-3-carbamoyloxymethyl-3-cephem-4-carboxylic acid. *Tetrahedron Lett.* 1972: 1585~1588, 1972
- 7) HASHIGUCHI, S.; Y. MAEDA, S. KISHIMOTO & M. OCHIAI: A study on the synthesis of carumonam starting from an  $\alpha$ -amino acid. *Heterocycles* 24: 2273~2283, 1986
- 8) NAITO, T.; S. ABURAKI, H. KAMACHI, Y. NARITA, J. OKUMURA & H. KAWAGUCHI: Synthesis and structure-activity relationships of a new series of cephalosporins, BMY-28142 and related compounds. *J. Antibiotics* 39: 1092~1107, 1986
- 9) NAGASAWA, J.; Y. ARAKI & Y. ISHIDO: Preparation of vinyl diacetate. *J. Org. Chem.* 46: 1734~1736, 1981